Biorepository, Pathology, and Immune Monitoring Core

摘要-生物信息库、病理学和免疫监测核心(核心3) 生物库、病理学和免疫监测核心(核心3)将成为 该孢子在脑癌中的三个项目和发展计划通过提供全面的 生物仓库银行，完整的表型和基因型组织病理学评估，以及最先进的 免疫监测。这一资源将由一组非常有成就的研究科学家提供 有数十年使用这些平台的经验，同时患有既往和当前的癌症 免疫疗法试验。我们的生物库资源已经积累了超过33,000个冷冻肿瘤块，包括 超过21,000对中枢神经系统肿瘤样本，与匹配的血液样本在-170℃的存储中 从2687名患者中选出。工作人员接受了良好实验室操作规范(GLP)方面的培训，生物库是 由美国病理学家学会认证。样本与杜克医院的病理报告有关 其中包括诊断、增殖、表型和基因型数据的概况，以便研究人员 接触到具有良好特征的肿瘤组织。这个核心也有广泛的人类免疫图谱的历史 使用杜克大学高度标准化和经过验证的分析方法，从而提供了广泛的最新技术 全面询问免疫疗法免疫反应的技术平台。流动 基于细胞学的表型和功能免疫图谱平台在这方面表现出了特别的优势 基于过去和正在进行的广泛应用以及对这些工具在 疫苗和癌症免疫治疗试验和熟练程度测试工作的背景。此外，所有人都免疫 将根据Good临床实验室进行孢子相关临床试验的监测 实践(GCLP)。具体目标是1)提供血液和组织分配和跟踪服务， 组织诊断、免疫组织化学(IHC)和生物库对项目临床及相关的支持 学习。2)为参加项目的患者提供符合GCLP的全面免疫监测 使用标准化和经验证的最先进的基于流式细胞术的免疫图谱的临床研究 站台。该核心还将继续创新，包括通过翻译创新的方法 开发这一核心来分析脑瘤的异质性和免疫反应进入诊断， 床边的预后和治疗反应性临床测试。此外，还有孢子间 免疫监测联盟将继续分享新免疫图谱的开发和验证 平台，同时也试图标准化标本获取、准备、运输和 根据一套统一的标准操作程序(SOP)进行评估。

ABSTRACT – Biorepository, Pathology, and Immune Monitoring Core (Core 3) The Biorepository, Pathology, and Immune Monitoring Core (Core 3) will serve as a critical resource for the three projects and developmental programs of this SPORE in Brain Cancer by providing comprehensive biorepository banking, complete phenotypic and genotypic histopathologic assessment, and state-of-the-art immune monitoring. This resource will be provided by a team of highly accomplished research scientists who have decades of experience with these platforms in conjunction with previous and current cancer immunotherapy trials. Our Biorepository resource has accumulated over 33,000 frozen tumor blocks, including over 21,000 paired central nervous system tumor samples, in -170oC storage with matched blood samples from over 2,687 patients. The staff are trained in Good Laboratory Practices (GLP) and the Biorepository is certified by the College of American Pathologists. Samples are linked with Duke Hospital Pathology reports that include a profile of diagnostic, proliferative, phenotypic, and genotypic data in order that researchers have access to well characterized tumor tissues. This Core also has an extensive history of human immune profiling using highly standardized and validated assays at Duke, thus providing a broad repertoire of state-of-the-art technology platforms to comprehensively interrogate immune responses to immunotherapy. The flow cytometry-based phenotypic and functional immune profiling platforms represent a particular strength in this proposal, based on the extensive past and ongoing applications as well as refinements of these tools in the context of vaccine and cancer immunotherapy trials and proficiency testing efforts. Additionally, all immune monitoring of SPORE-associated clinical trials will be performed according to Good Clinical Laboratory Practices (GCLP). The specific aims are 1) To provide blood and tissue distribution and tracking services, tissue diagnosis, immunohistochemical (IHC) and biobanking support to the Projects' clinical and correlative studies. 2) To provide GCLP-compliant, comprehensive Immune Monitoring of patients enrolled in the Projects' clinical studies using standardized and validated state-of-the-art flow cytometry-based immune profiling platforms. This Core will also continue to innovate, including by translating innovative methodologies developed to analyze brain tumoral heterogeneity and immune responses in this Core into diagnostic, prognostic, and therapeutic responsiveness clinical tests for the bedside. In addition the Inter-SPORE consortium for immune monitoring will continue to share development and validation of new immune profiling platforms while also attempting to standardize all aspects of specimen acquisition, preparation, transport, and evaluation according to a uniform set of Standard Operating Procedures (SOPs).